Table 1 Baseline characteristics of reviewed documents (N = 45)
From: What are the drivers of recurrent cholera transmission in Nigeria? Evidence from a scoping review
Characteristic | Frequency (%) |
|---|---|
General characteristics | |
Authors’ affiliation | |
 Academic institution | 22 (48.89) |
 Academic and government | 7 (15.56) |
 Academic and hospital | 1 (2.22) |
 Academic and International NGO | 1 (2.22) |
 Governmental health institution | 12 (26.67) |
 Governmental health institution and International NGO | 1 (2.22) |
 International NGO | 1 (2.22) |
Document type | |
 Conference proceeding | 5 (11.11) |
 Peer-reviewed journal | 40 (88.89) |
Publication period | |
  < 1990 | 4 (8.89) |
 1990–2000 | 6 (13.33) |
 2001–2010 | 6 (13.33) |
 2011–2018 | 29 (64.44) |
State where study was undertaken | |
 Akwa-Ibom and Cross-River | 1 (2.22) |
 Bauchi | 1 (2.22) |
 Bauchi and Gombe | 1 (2.22) |
 Bauchi, Borno and Gombe | 2 (4.44) |
 Bauchi, Borno and Osun | 1 (2.22) |
 Benue | 1 (2.22) |
 Borno | 2 (4.44) |
 Cross-River | 4 (8.89) |
 Jigawa | 2 (4.44) |
 Kaduna | 4 (8.89) |
 Kano | 2 (4.44) |
 Katsina | 1 (2.22) |
 Lagos | 2 (4.44) |
 Nasarawa | 1 (2.22) |
 Niger | 1 (2.22) |
 Ogun | 1 (2.22) |
 Osun | 2 (4.44) |
 Oyo | 7 (15.56) |
 Rivers | 1 (2.22) |
 Multiple states (> 3 states) | 8 (17.78) |
Study context | |
 Epidemic | 29 (64.44) |
 Endemic | 9 (20.00) |
 Endemic and epidemic | 6 (13.33) |
 Unspecified | 1 (2.22) |
Study approach | |
 Prospective | 18 (40.00) |
 Retrospective | 23 (51.11) |
 Prospective and retrospective | 3 (6.67) |
 Unclear | 1 (2.22) |
Study design | |
 Case-control | 10 (22.22) |
 Cross-sectional | 28 (62.22) |
 Review | 4 (8.89) |
 Unspecified | 3 (6.67) |
Median sample size reported in documents (IQR)a | 329 (109–1220) |
Age group of study participants | |
 All age groups | 17 (37.78) |
 Adults | 2 (4.44) |
 Children under-5 years | 1 (2.22) |
 Children under-14 years | 1 (2.22) |
 Unspecified | 24 (53.33) |
Funding for study | |
 Unspecified | 41 (91.11) |
 Yes | 4 (8.89) |
Ethical approval for the study | |
 Unspecified | 34 (75.56) |
 Yes | 11 (24.44) |
Clinical characteristics | |
Data collection approach | |
 Record extraction | 4 (8.89) |
 Microbiological examination | 7 (15.56) |
 Questionnaire | 9 (20.00) |
 Record extraction and microbiological examination | 1 (2.22) |
 Questionnaire and microbiological examination | 9 (20.00) |
 Record extraction and questionnaire | 2 (4.44) |
 Record extraction, questionnaire and microbiological examination | 1 (2.22) |
 Record extraction, questionnaire and observation | 2 (4.44) |
 Unspecified | 10 (22.22) |
Report of case fatality rate (%) | |
 No | 23 (51.11) |
 Yes | 22 (48.89) |
Mean (SD) case fatality rateb | 6.53 (3.90) |
Report of attack rate | |
 No | 40 (88.89) |
 Yes | 5 (11.11) |
Location of sample collection | |
 Community | 11 (24.44) |
 IDP camp | 1 (2.22) |
 Primary | 1 (2.22) |
 Secondary | 1 (2.22) |
 Tertiary | 4 (8.89) |
 Primary and secondary | 1 (2.22) |
 Secondary and tertiary | 3 (6.67) |
 Tertiary and private | 1 (2.22) |
 Unspecified health facility | 2 (4.44) |
 Unspecified health facility and community | 4 (8.89) |
 Unspecified health facility and IDP camp | 1 (2.22) |
 Unspecified | 15 (33.33) |
Culture | |
 No | 11 (24.44) |
 Yes | 22 (48.89) |
 Unspecified | 12 (26.67) |
Rapid diagnostic test performed | |
 No | 40 (88.89) |
 Yes | 5 (11.11) |
Identified biotype | |
 Classical | 1 (2.22) |
 El-Tor | 4 (8.89) |
 Classical & El-Tor | 2 (4.44) |
 Atypical El-Tor | 1 (2.22) |
 Unspecified | 37 (82.22) |
Identified serogroup | |
 O1 | 13 (28.89) |
 Non-O1 | 2 (4.44) |
 Unspecified | 30 (66.67) |
Identified serotype | |
 Ogawa | 8 (17.78) |
 Inaba | 1 (2.22) |
 Ogawa and Inaba | 1 (2.22) |
 Unspecified | 35 (77.78) |